Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

5303 - Real Life Use of Talimogene Laherparepvec in Melanoma in Centers in Austria and Switzeland


30 Sep 2019


Poster Display session 3


Tumour Site



Christoph Hoeller


Annals of Oncology (2019) 30 (suppl_5): v533-v563. 10.1093/annonc/mdz255


C. Hoeller1, J.M. Ressler2, M. Karasek3, V. Aedo Lopez4, L. Koch5, H. Kehrer6, P. Koelblinger7, F. Weihsengruber8, J. Kofler9, E. Richtig10, O.A. Michielin11, C. Hafner12

Author affiliations

  • 1 Department Of Dermatology, Medizinische Universitaet Wien (Medical University of Vienna), 1090 - Vienna/AT
  • 2 Department Of Dermatology, Medical University of Vienna, 1090 - Vienna/AT
  • 3 Dpt. Of Dermatology, University Hospital St. Poelten, 3100 - St. Poelten/AT
  • 4 Service D'oncologie, CHUV - Centre Hospitalier Universitaire Vaudois, 1011 - Lausanne/CH
  • 5 Dpt. Of Dermatology, Medical University of Graz, 8036 - Graz/AT
  • 6 Dpt. Of Dermatology, Krankenhaus der Elisabethinen, 4010 - Linz/AT
  • 7 Dpt. Of Dermatology, Paracelsus Medical University, 5020 - Salzburg/AT
  • 8 Department Of Dermatology And Venerology, Krankenanstalt Rudolfstiftung, 1200 - Vienna/AT
  • 9 Dpt. Of Dermatology, Landeskrankenhaus LKH Klagenfurt am Woerthersee, 9020 - Klagenfurt/AT
  • 10 Dpt. Of Dermatology, Institute of Pathology, Medical University of Graz, 8036 - Graz/AT
  • 11 Oncology, Centre Hospitalier Universitaire Vaudois - CHUV, 1011 - Lausanne/CH
  • 12 Department Of Dermatology, University Hospital St. Pölten, Karl Landsteiner University of Health Sciences, 3100 - St Pölten/AT


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5303


Talimogene Laherparepvec (TVEC), a genetically modified GM-CSF expressing HSV1 Virus that preferentially replicates in tumor cells is approved in Europe for use in melanoma patients with injectable metastatic lesions in stage III-IVM1a. Approval was based on the OPTIM study which did also include patients with distant metastases and demonstrated a ORR of 40.5% and a CR rate of 16.6%. The aim of this study was to assess the outcome of melanoma patients treated with TVEC in a real life clinical setting outside of clinical studies.


To this aim a retrospective chart review in 7 melanoma centers in Austria and 1 center in Switzerland was conducted and anonymized data on disease stage, treatment duration, treatment response by investigator assessment following RECIST 1.1, tolerability as well as data on follow up therapies was collected.


A total of 62 patients received TVEC since December of 2016. The majority of patients were AJCC stage IIIB and IIIC. Two patients with stage IV M1b and M1d who had complete control of their distant metastases and a locoregional progression were treated in parallel with a PD-1 antibody in one case and in parallel with a BRAF/MEK inhibitor combination in the other. In 3 other cases TVEC was used in combination with a PD-1 inhibitor as first-line of therapy. The median number of intralesional injection cycles was 11. The ORR was 67,7%; 50% of patients achieved a complete remission. 7 of 31 patients with a CR had a subsequent progression, 4 with distant and 3 with locoregional metastases. The main side effects observed were fever and chills.


In this real life cohort treatment of TVEC shows a high overall and complete remission rate with the majority of complete responses being durable.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


C. Hoeller: Advisory / Consultancy, Speaker Bureau / Expert testimony: Amgen. J.M. Ressler: Speaker Bureau / Expert testimony: Amgen. H. Kehrer: Advisory / Consultancy: Amgen. P. Koelblinger: Advisory / Consultancy: Amgen. F. Weihsengruber: Advisory / Consultancy: Amgen. J. Kofler: Advisory / Consultancy: Amgen. E. Richtig: Advisory / Consultancy, Speaker Bureau / Expert testimony: Amgen. O.A. Michielin: Advisory / Consultancy, Speaker Bureau / Expert testimony: Amgen. C. Hafner: Advisory / Consultancy: Amgen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.